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Abstract
Background: Dopamine receptor 2 (DR2) expressions on B cells from Rheumatoid arthritis (RA) patients has been
found to be negatively correlated with disease activity and can potentially predict the response to treatment. This
study aimed to investigate the role of B cell DR2 expression on bone remodeling in RA.
Methods: Patients with RA (n = 14) or osteoarthritis (OA; n = 12), and healthy controls (n = 12) were recruited for
this study. Dopamine receptor (DR) 2 expression was assessed using flow cytometry. Pro-inflammatory cytokines,
including interleuin(IL)-1β, IL-6, IL-17, and tumor necrosis factor(TNF)-α, and bone turnovers, including osteocalcin
(OC),serum procollagen type I N propeptide (PINP), C-terminal telopeptide of type I collagen (β-CTX), collagen type
I cross-linked telopeptide (ICTP), as well as matrix metalloproteinase-3 (MMP-3) and osteoprotegerin (OPG) were
measured by electrochemiluminescence, chemiluminescence, or enzyme-linked immunosorbent assay. DR2
expression on synovial B cells from 4 RA patients and 3 OA patients was detected by immunofluorescence.
Results: There were more DR2+CD19+ B cells in synovial tissues from RA patients than in those from OA patients.
The frequency of peripheral B cells that expressed DR2 was positively correlated with plasma TNF-α level. Levels of
ICTP and MMP-3 were significantly higher, and OPG were lower in RA patients compared to those in the OA group
and healthy controls (all P < 0.05).
Conclusion: The frequency of B cells that expressed DR2 showed a correlation with levels of the pro-inflammatory
cytokine TNF-α. DR2+CD19+ B cells in synovial tissues might have a role in bone metabolism and TNF-α production.
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Background
Accumulating evidence has demonstrated that the
immune and skeletal systems share an abundance of
molecules and regulatory mechanisms, including cyto-
kines, receptors, signaling molecules, and transcription
factors, are the focus of the field of osteoimmunology
[1]. The dynamic homeostasis of bone formation and
resorption can be disrupted in many autoimmune disor-
ders because dysregulated immune responses can trigger
inflammation and accelerate the activation of osteoclas-
togenesis. As a prototypical immune disease, rheumatoid
arthritis (RA) is a type of chronic inflammatory arthritis
characterized by juxta-articular bone destruction and
systemic osteoporosis [2], which is closely related to the
course of disease and disability. B cells, which play a key
role in humoral immunity, are one of the most
important cell types in osteoimmunology. B cells are
uniquely endowed with osteointeractive properties, as
they can induce osteoclastogenic effects by secreting
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inflammatory cytokines or autoantibodies, directly acti-
vate osteoclasts via cell-cell contact, or potentially act as
the precursors of osteoclasts [3].
Reciprocal effects have also been observed between the
neurological and immune systems. These connections have
been extensively studied and are the focus of the interdis-
ciplinary field of neuroimmunology [4]. The dopaminergic
system, which consists of dopamine and dopamine
receptors (DRs), is a critical neurological pathway that can
modulate the immune system [5]. Dopamine targets one of
five receptors, namely DR1–DR5, to produce distinct
effects on the survival, differentiation, proliferation,
polarization, and apoptosis of immune cells, as well as
inducing different cytokine profiles. Altered expression of
dopamine receptors has been observed in many auto-
immune disorders [6].
Interestingly, the dopaminergic system also has tight re-
lationship with the skeletal system. Increased dopamine
receptor expression has been observed in synovial fibro-
blasts in RA [7]. Genetic polymorphisms in DR4 have
been significantly associated with bone mineral density in
Japanese men [8]. Neuroleptic treatment in Parkinson’s
disease using a D2-like receptor antagonist has been
reported to lead to osteoporosis [9]. Additionally, activa-
tion of the D2-like receptor inhibits osteoclastogenesis by
directly affecting osteoclast formation, and antagonizing
the D1-like receptor pathway to suppress bone and
cartilage destruction in both mice with collagen-induced
arthritis [10] and in humanized RA/SCID mice [11].
Previously, we found that DR2 expression in B cells is
negatively correlated with disease activity in RA patients
and can reflect patient responses to disease modifying
antirheumatic drug therapy [12]. As the immune, bone,
and dopaminergic systems are interconnected, we
sought to further investigate the relationships between
these systems and to gain a better understanding of the
pathogenesis of RA. Herein, bone turnovers and inflam-
matory cytokine levels were measured in patients with
RA at baseline and after drug therapy, and were com-
pared with the frequency of B cell DR2 expression. We
also measured B cell DR2 expression at the bone–syn-
ovial interface. Since the DR2 expressed on the B cells
might play a pivotal role in the generation and amplifica-
tion of focal inflammation.
Methods
Study population
A total of 14 RA patients were included in this study and
all patients satisfied the 1987 American College of Rheuma-
tology classification criteria for RA [13]. Additionally, 12
healthy volunteers and osteoarthritis (OA) patients
diagnosed according to the classical classification criteria
[14] were recruited as controls. Inclusion criteria for the
RA group included patients with active disease (28-joint
disease activity score [DAS28] according to the CRP for-
mula > 3.2) and disease modifying anti-rheumatic drug
(DMARD) naive or no DMARDs use within the previous
3 months. Patients who had previously received anti-tumor
necrosis factor-α (TNF-α) or glucocorticoid therapy were
excluded. The other exclusion criteria for both the RA and
OA groups were the followings: infectious or inflammatory
disease, an endocrine disorder, any past or current psychi-
atric or neurological diseases, pregnant or planning to be
pregnant, lactation, liver or kidney dysfunction, cardiovas-
cular disease, cancer, any drug history that would affect the
sympathomimetric or sympatholytic system, and recent se-
vere stress events. This study was performed according to
the Declaration of Helsinki and approved by the Medical
Ethics Committee of the Zhongshan Hospital. All patients
provided written informed consent.
Sample preparations
Anti-coagulating peripheral blood (10 ml) from the
cubital vein was obtained before (i.e., at baseline) and
3 months after the initiation of treatment. Peripheral
blood mononuclear cells were separated using Ficoll–
Hypaque density centrifugation and prepared at a final
concentration of 1 × 106 cells/ml. Plasma was separated
and stored at −80 °C. Synovial tissue samples were ob-
tained from another 4 patients with RA and 3 patients
with OA who had been diagnosed according to the clas-
sic classification criteria and undergone knee joint re-
placement surgery. Fat tissue was carefully removed
from the synovial tissue. Dissected samples were imme-
diately fixed in O.C.T. (Sakura Finetek, Japan), quickly
frozen, and stored at −80 °C until later use.
DR2 detection on peripheral B cells by flow cytometry
B cells from PBMCs were labeled with anti-human allo-
phycocyanin (APC)-conjugated CD19 antibody (Becton
Dickinson, San Jose, CA, USA) and DR2 antibody (Life
Span BioSciences, Seattle, WA, USA) at 4 °C for 30 min.
Cells were washed twice with staining buffer and
incubated with secondary CF405M-conjugated goat anti-
rabbit antibody (Sigma–Aldrich, St. Louis, MO, USA;
1:100 dilution) at 4 °C for 30 min. A ‘no primary anti-
body’ control and a normal rabbit sera (Rab) control
(1:100) were used as two separate negative controls.
Stained cells were analyzed using a Canto II flow cyt-
ometer (BD Biosciences). Data analysis was performed
with Diva software (BD Biosciences) and FlowJo V.7.6.4
(Treestar Inc., Ashland, OR, USA). A minimum of 1 × 106
cells were analyzed from each sample. The results were fi-
nally expressed as the percentage of positive cells (%).
BDR2 (%) indicated the percentage of CD19+DR2+ cells
among total CD19+ cells.
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Measurement of cytokines and bone turnover
Biochemical markers of bone formation—Osteocalcin
(OC) or serum procollagen type I N propeptide (PINP),
and bone resorption—C-terminal telopeptide of type I
collagen (β-CTX) or collagen type I cross-linked
telopeptide (ICTP), as well as matrix metalloproteinase
3 (MMP3) and osteoprotegerin (OPG) were tested.
Plasma OC, PINP, and β-CTX were measured using an
electrochemiluminescence immunoassay with automated
immunoassay analyzers (Elecsys and Cobas e601 Analyzer,
2010, Roche Diagnostics GmbH, Mannheim, Germany)
and reagents were supplied by Roche Diagnostics (Roche
Diagnostics GmbH). The total CV was <6 %. Plasma ICTP
was measured manually using an ELISA kit from Orion
Diagnostics (Orion Corporation, Orion Diagnostica,
Espoo, Finland). The normal range of serum ICTP was
1.8–5.0 ng/ml. Inter-assay CVs for ICTP were 4–9 %.
Quantification of levels of the pro-inflammatory cytokines
interleukin-1β (IL-1β), IL-6, and TNF-α in plasma were
conducted on a Siemens Immulite 1000 immunoassay
platform. IL-17 and MMP3 protein expression levels were
measured in plasma by using specific ELISA kits (R&D
Systems Europe, Abingdon, UK). The ELISA standard
curve range for IL-17 was from 15 to 1000 pg/ml. Plasma
OPG was measured using a highly sensitive quantitative
sandwich ELISA (Sigma–Aldrich) test. Intra- and inter-
assay coefficients of variation were 2.36 % and 5.97 %,
respectively.
Immunohistochemical analysis of human synovial tissues
Immunohistochemistry was performed following stand-
ard protocols. In brief, cyosections (5 μm) were air-dried
for 1 h at room temperature. After fixation with acetone
for 10 min, sections were washed with phosphate-
buffered saline. Nonspecific binding sites were blocked
with goat serum for 60 min at 37 °C. Samples were incu-
bated with DR2 primary antibody and APC-conjugated
CD19 antibody overnight at 4 °C. The next day, sections
were thoroughly washed with PBS, and then were incu-
bated with specific Alexa Fluor 488- and Alexa Fluor
647-conjugated antibodies (Sigma–Aldrich) for 45 min.
Sections were counterstained with 4′-6-Diamidino-2-
phenylindole dihydrochloride (DAPI; Sigma–Aldrich).
Samples were mounted with glycerol glycine and cov-
ered with a coverslip. Every antibody was tested using
single staining for specificity and autofluorescence.
Staining with the secondary antibodies alone was per-
formed in parallel as negative control, and no positive
staining was observed.
Statistical analysis
Continuous data were expressed as means ± standard
deviation (SD) or medians (inter-quartile range, IQR) ac-
cording to the data distribution. Normal distribution of
data was confirmed using the Kolmogorov–Smirnov test.
Statistical significance was evaluated by Student’s t-test.
For non-parametric data, the Mann–Whitney U-test was
used. The Spearman’s correlation coefficient was used
for correlation analyses. All statistical analyses were
carried out using the Statistical Package for the Social
Sciences (SPSS) V.20. P-values <0.05 were considered in-
dicate statistically significant differences.
Results
General characteristics
Among the 14 RA patients included in this analysis, 11
were female (78.57 %). The mean age of the RA patients
was 54.29 years old (SD, 14.96; range, 20–77). As controls,
12 OA patients and 12 healthy donors were also recruited;
their ages were 56.75 ± 9.19 and 24.58 ± 2.07 years old, with
male/female ratios of 1:1 and 1:2, respectively. All RA
patients had moderate to high disease activity (DAS 286.29
± 1.15). The frequency of cells showing positive staining for
DR2 in the healthy control, RA, and OA groups were
28.1 % (14.38 %–42.35 %), 3.58 % (2.58 %–8.13 %), and
6.76 % (2.44 %–15.85 %), respectively. RA patients had
lower frequencies of DR2-expressing cells in contrast to the
healthy controls (P = 0.006), and had no statistical differ-
ence with OA patients (P = 0.547) (Fig. 1).
Bone turnover and inflammatory markers
Serum levels of the cytokines IL-1β, TNF-α, IL-6, and
IL-17 were measured. IL-1β levels did not differ among
the three groups (<5 pg/ml). IL-6 was higher at baseline
in the RA group (median, 9.70 pg/ml; IQR, 7.9–
71.95 pg/ml) than in the OA group (median, 2.60 pg/ml;
IQR, 2.0–2.70 pg/ml; P < 0.001) or the healthy controls
(median, 2.00 pg/ml; IQR, 2.0–2.38 pg/ml; P < 0.001).
Levels of TNF-α in the RA group (median: 16.2 pg/ml;
IQR, 12.53–24.00 pg/ml) were remarkably higher com-
pared to the healthy controls (median, 10.45 pg/ml; IQR,
8.05–17.33 pg/ml; P = 0.017) and the OA group (median,
14.4 pg/ml; IQR, 11.03–20.58 pg/ml), although this dif-
ference was not statistically significant (P = 0.410). Levels
of IL-17 were below the limit of detection in the healthy
controls and OA group, and were higher than 15 pg/ml
in 14 RA patients.
The levels of OC and PINP, which are markers of bone
formation, did not differ among the three groups. ICTP
and β-CTX levels mainly reflect the rate of bone resorp-
tion. The mean levels of β-CTX in the RA group were not
significantly different from those in the OA group or
healthy controls (P > 0.05). ICTP, which is a more sensitive
marker, was higher in the RA group (5.52 ± 5.14 μg/L)
than in the healthy controls (2.05 ± 0.71 μg/L, P < 0.001)
or the OA group (2.45 ± 0.9 μg/L, P < 0.001). RA patients
exhibited increased baseline plasma levels MMP3 (29.93
± 18.57 ng/ml), which is a molecule responsible for
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degradation of the extracellular matrix, compared with
the healthy controls (12.79 ± 8.17 ng/ml, P = 0.007) and
the OA group (5.25 ± 1.95 ng/ml, P < 0.001). Levels of
OPG were significantly reduced in RA patients compared
with those of healthy controls (P < 0.001) or OA patients
(P = 0.001). The concentrations of bone and inflammatory
biomarkers are shown in Table 1.
Correlations between DR2 expression on B cells and
levels of bone turnover and inflammatory markers in the
plasma
Associations between the frequencies of B cells express-
ing DR2 with levels of inflammatory and bone turnover
markers were analyzed using Spearman correlation tests.
We found that B cell DR2 expression had a negative
correlation with TNF-α level in RA patients (r = −0.622,
P = 0.018; Fig. 2). The secretions of TNF-α, IL-6 and IL17
have been demonstrated to cause synovial inflammation
[15], However, DR2 was not associated with other cyto-
kines except for TNF-α and bone turnover markers.
DR2 expression on B cells in synovial tissues
In the RA synovium, clusters of B cells could be ob-
served at the sites of inflammation. Many B cells were
found to express DR2 (Fig. 3a). Compared with RA syn-
ovial tissues, the inflammation was less severe and fewer
B cells were found in whole sections from OA patients.
Accordingly, few DR2+CD19+ B cells were detected in
the OA patient samples (Fig. 3b). These distinct patho-
logical findings were a consequence of the different im-
munopathologies involved in RA and OA.
Fig. 1 Representative FACS plots of DR2-expressing cells in patients with RA, OA and healthy controls







TNF-α (pg/ml) 10.45 (8.05, 17.33) 14.4 (11.03, 20.58) 16.2 (12.53, 24.00)*
IL-1β (pg/ml) <5 <5 <5
IL-6 (pg/ml) 2.00 (2.0, 2.38) 2.60 (2.0, 2.70) 9.70 (7.9, 71.95)*,**
IL-17 (pg/ml) <15 <15 17.99 ± 1.81
ICTP (μg/L) 1.79 (1.59, 2.50) 2.22 (1.68, 3.11) 4.40 (2.98, 5.28)*,**
OC (ng/ml) 17.33 ± 4.43 14.25 ± 4.13 16.33 ± 8.81
β-CTX (ng/ml) 0.33 (0.25, 0.42) 0.47 (0.35, 0.56)* 0.28 (0.19, 0.43)
PINP (ng/ml) 48.07 ± 14.99 53.31 ± 16.73 48.89 ± 21.39
MMP-3 (ng/ml) 12.79 ± 8.17*** 5.25 ± 1.95*** 29.93 ± 18.57
OPG (pg/ml) 156.14 (151.48, 161.96) 96.45 (87.45, 145.37)* 73.79 (59.88, 89.75)
Continuous data are expressed as means ± standard deviation (SD) or medians (inter-quartile range, IQR) according to the data distribution
Abbreviations: TNF-α tumor necrosis factor-α; IL-1β interleukin-1β, IL-6 interleukin-6, IL-17 interleukin-17, ICTP collagen type I cross-linked telopeptide, OC osteocalcin,
PINP procollagen type I N propeptide, β-CTX C-terminal telopeptide of type I collagen, ICTP collagen type I cross-linked telopeptide, MMP3 matrix metalloproteinase 3,
OPG osteoprotegerin
*P < 0.05 compared to healthy controls using the Mann–Whitney U-test
**P < 0.05 compared to the OA group using the Mann–Whitney U-test
***P < 0.05 compared to the RA pretreatment group using Student’s t-test
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Discussion
Bone remodeling results from the dynamic balance of
bone resorption and formation, and is subject to com-
plex modes of regulation [16]. Imbalanced bone remod-
eling in RA leads to arthropathies, which include joint
erosion and systemic osteoporosis. Dysregulated im-
mune system and neuropeptides, such as dopamine, feed
into the complex regulatory machinery that controls
bone remodeling. One influence of immune signals can
be to trigger disequilibrium of bone remodeling by af-
fecting the differentiation of osteoclasts or the secretion
of pro-inflammatory cytokines. Additionally, accumulat-
ing evidence indicates an intriguing role for the dopa-
minergic system in fine-tuning immune responses [17]
and exerting direct effects on bone resorption [18].
Therefore, the fields of neuroimmunology and osteoim-
munology are tightly integrated.
However, this composition of this intricate regulatory
network remains obscure. In this present study, we in-
vestigated how the immune system, together with the
dopaminergic system, can regulate bone metabolism,
which determines disease manifestations and prognoses
in RA patients. Previously, we showed that DR2 expres-
sion was negatively related to disease activity, and other
DRs have been correlated with acute phase reactants or
clinical manifestations. B cells are one of the most im-
portant drivers of immunopathologies, and pathological
findings also support that B cells could contribute to
both the initiation and perpetuation of pathogenic im-
mune responses in RA [19]. Reports of the efficacy of B
cell depletion in RA patients revitalized interest in the
pathogenic role of B cells in RA. To further explore the
relationship between DR2 expression level on B cells
and bone metabolism, we analyzed levels of plasma
markers of bone turnover and pro-inflammatory cyto-
kines that might influence bone remodeling. Markers for
bone turnover can be measured to detect differences in
bone formation, resorption, further risk of fracture, and
treatment responses in RA [20]. These biochemical
markers show changes before bone mineral density
changes that occur because of abnormal bone metabol-
ism. Our findings indicated that MMP3 levels in RA pa-
tients were higher than those in OA patients and healthy
controls (P = 0.007 and P < 0.001, respectively). ICTP,
which is derived from MMP, could discriminate between
RA patients from healthy individuals or OA patients, as
well as MMP3. ICTP is a sensitive marker for periarticu-
lar bone resorption that is linked to the activity of
MMPs in various cells, such as synoviocytes [21]. The
RA patients which were in moderate to high disease ac-
tivity had high levels of IL-17, IL-6 and TNF-α, suggest-
ing that inflammation promotes the bone destruction.
Our data also showed that MMP3 and ICTP represent
Fig. 2 Spearman correlation analysis of DR2 expression and TNF-α
level in RA patients
Fig. 3 In-situ immunofluorescence stainings of B cell DR2 expressions in the synovial tissues. a and b Representative images of DR2 expression on B
cells from RA (N = 4) and OA (N = 3) patients are shown. Sections were counterstained with DAPI (blue) to allow visualization on nuclei; magnification,
400×. DR2-positive cells are marked by an arrowhead
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effective biomarkers that reflect bone erosion associated
with RA [22]. Although the correlation analyses indi-
cated that DR2 expression on B cells from peripheral
blood showed no association with bone turnovers, the
previous report demonstrated the DR2 expressions on B
cells were negatively correlated with disease activity.
Therefore the focal expressions of DR2 on B cells found in
synovial tissue might regulate the bone metabolism
through affecting the inflammatory responses. TNF-α as a
pro-inflammatory cytokine associated with bone metabol-
ism can induce osteoclast activation and differentiation.
TNF-α causes the osteoclast-induced bone destruction
and can inhibit osteoblast differentiation and apoptosis
[23]. TNF-α acts on chondrocytes to induce the synthesis
of proteases, such as collagenase and matrix metallopro-
teinase, which can cause cartilage destruction [24].
Significant associations between treatment with TNF-α
antagonists and the suppression of bone loss have also
been described in many studies [25–27].
Previously, 10–25 % of infiltrating lymphocytes in RA
synovial tissues have been reported to be B cells; however,
this number might be an underestimate [28]. The syn-
ovial–bone interface in RA is an active site of germinal
center formation, B-cell accumulation, plasma cell differ-
entiation, in situ antibody production, and cytokine secre-
tion [29]. Yeo et al. identified synovial fluid CD19+ B cells
as the dominant producers of RANK-L at both the mRNA
and protein levels. Compared to B cells in the peripheral
blood, a higher proportion of these cells in the synovial
fluid expressed RANK-L [30]. Our data showed that the
distribution of B cells was mostly confined to clusters at
sites of inflammation, as well as isolated cells or pairs of
cells that infiltrated the synovium when viewed in the
positive field. There were more infiltrating DR2+CD19+ B
cells in the RA synovium than in the OA synovium. This
finding laid the foundation for establishing the potential
role of B cell expression of DR2 in modulating bone
remodeling. However, in addition to B cells, a wide
spectrum of cells expresses DRs, as we observed in our
present study. Silvia et al. reported that DRs are also
expressed by T cells, fibroblasts, and macrophages [7]. In
2003, a genotyping study from a group in Japan reported
that the DR4 gene was significantly associated with bone
mineral density and markers of bone resorption in men,
establishing it as a candidate locus for predicting bone loss
in Japanese individuals [8]. Subsequently, Martín et al. re-
ported a significant positive association of urine dopamine
levels with bone mass in the general population, which
was not observed for other catecholamines [31]. The rela-
tionship between the dopaminergic system and bones was
further explored in both animal models and ex vivo
analyses. The D1-like receptor antagonist SCH23390
attenuated radiological joint destruction in mice with
collagen-induced arthritis. Furthermore, the addition of
SCH23390 inhibited osteoclastogenesis in a dose-
dependent manner [10]. Another study by Nakano et al.
characterized the effects of the dopaminergic system on
the IL-6–IL-17 axis. Dopamine produced by DCs can in-
duce IL-6-dependent secretion of IL-17, which is crucial
for Th17 cell differentiation. SCH23390 can suppress the
IL-6–Th17 axis, thereby alleviating cartilage destruction
in a humanized RA/SCID mouse chimera model [7].
The present study has certain limitations. First, though
our preliminary results demonstrated interest effects of
dopamine receptor 2 expression on B cells on bone
metabolism and TNF-α levels, these just indicated the
phenomenon, the underlying mechanism remain to be elu-
cidated in further study. The pending questions include
that whether TNF was secretion from DRD2 +CD19+ B-
cells and whether DRD2 expression on CD19+ B-cells is
regulated by TNF stimulation. Second, the differences in
DRD2 expression levels at each phase of B-cell differenti-
ation should be done in the future to get better understand
of the role of DRD2 expression on B-cells in the patho-
genesy. Third, whether and how DR2 expression on B cells
could affect T cells and other inflammatory cells, which
might further promote the secretion of proinflammatory
mediators, needs to be established. Finally, the limited pa-
tient cohort size should be expanded and more age and
sex-matched controls would be enrolled in future studies.
Conclusion
In conclusion, our study for the first time showed that
infiltrating B cells express DR2 in RA synovial tissue,
implicating that it might act to regulate bone remodel-
ing. DR2 expression on B cells from the peripheral blood
was negatively associated with levels of the proinflam-
matory cytokine TNF-α. This finding suggested that in-
flammation might be an important link between the




This study was supported by Shanghai Committee of Science and Technology
(Grant No. 12JC1402500).
Availability of data and material
The datasets during and/or analysed during the current study available from
the corresponding author on reasonable request.
Authors’ contributions
Designed the experiments: LDJ, YS and LW. Contributed to the writing of
the manuscript: LW and YS. LW and XFK performed the experiments.
Analyzed the data: QZ and DYH. Contributed reagents/materials/analysis
tools: CZ and TY. All authors read and approved the final manuscript.
Competing interests
The authors declare that they have no competing interests.
Consent for publication
All patients enrolled in this study provided written informed consent.
Wei et al. BMC Musculoskeletal Disorders  (2016) 17:352 Page 6 of 7
Ethics approval and consent to participate
This study was performed according to the Declaration of Helsinki and
approved by the Medical Ethics Committee of the Zhongshan Hospital.
Author details
1Department of Rheumatology, Zhongshan Hospital, Fudan University, No.
180, Road Fenglin, Shanghai 200032, People’s Republic of China.
2Department of Orthopedics, Zhongshan Hospital, Fudan University,
Shanghai, China. 3Department of Rheumatology, Guanghua Integrative
Medicine Hospital, Shanghai, China. 4Center of evidence based medicine,
Fudan University, Shanghai, China.
Received: 17 December 2015 Accepted: 13 August 2016
References
1. Takayanagi H. Osteoimmunology: shared mechanisms and crosstalk
between the immune and bone systems. Nat Rev Immunol. 2007;7:292–304.
2. Jones SM, Bhalla AK. Osteoporosis in rheumatoid arthritis. Clin Exp
Rheumatol. 1993;11:557–62.
3. Manilay JO, Zouali M. Tight relationships between B lymphocytes and the
skeletal system. Trends Mol Med. 2014;20:405–12.
4. Mix E, Goertsches R, Zettl UK. Immunology and neurology. J Neurol. 2007;
254:II2–7.
5. Pacheco R, Contreras F, Zouali M. The dopaminergic system in autoimmune
diseases. Front Immunol. 2014;5:117.
6. Jafari M, Ahangari G, Saberi M, Samangoui S, Torabi R, Zouali M. Distorted
expression of dopamine receptor genes in systemic lupus erythematosus.
Immunobiology. 2013;218:979–83.
7. Capellino S, Cosentino M, Luini A, Bombelli R, Lowin T, Cutolo M, et al.
Increased expression of dopamine receptors in synovial fibroblasts from
patients with rheumatoid arthritis: inhibitory effects of dopamine on
interleukin-8 and interleukin-6. Arthritis Rheumatol. 2014;66:2685–93.
8. Yamada Y, Ando F, Niino N, Shimokata H. Association of a polymorphism of
the dopamine receptor D4 gene with bone mineral density in Japanese
men. J Hum Genet. 2003;48:629–33.
9. Wyszogrodzka-Kucharska A, Rabe-Jabłońska J. Decrease in mineral bone
density in schizophrenic patients treated with 2nd generation
antipsychotics. Psychiatr Pol. 2005;39:1173–84.
10. Nakashioya H, Nakano K, Watanabe N, Miyasaka N, Matsushita S, Kohsaka H.
Therapeutic effect of D1-like dopamine receptor antagonist on collagen-
induced arthritis of mice. Mod Rheumatol. 2011;21:260–6.
11. Nakano K, Yamaoka K, Hanami K, Saito K, Sasaguri Y, Yanagihara N, et al.
Dopamine induces IL-6-dependent IL-17 production via D1-like receptor on
CD4 naive T cells and D1-like receptor antagonist SCH-23390 inhibits
cartilage destruction in a human rheumatoid arthritis/SCID mouse chimera
model. J Immunol. 2011;186:3745–52.
12. Wei L, Zhang C, Chen HY, Zhang ZJ, Ji ZF, Yue T, et al. Dopamine receptor
DR2 expression in B cells is negatively correlated with disease activity in
rheumatoid arthritis patients. Immunobiology. 2015;220:323–30.
13. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS. The
American Rheumatism Association 1987 revised criteria for the classification
of rheumatoid arthritis. Arthritis Rheum. 1988;31:315–24.
14. Altman R, Asch E, Bloch D, Bole G, Borenstein D, Brandt K, et al.
Development of criteria for the classification and reporting of osteoarthritis.
Classification of osteoarthritis of the knee. Diagnostic and Therapeutic
Criteria Committee of the American Rheumatism Association. Arthritis
Rheum. 1986;29:1039–49.
15. Choy E. Understanding the dynamics: pathways involved in the pathogenesis
of rheumatoid arthritis. Rheumatology (Oxford). 2012;51 Suppl 5:v3–11.
16. Eriksen EF. Cellular mechanisms of bone remodeling. Rev Endocr Metab
Disord. 2010;11:219–27.
17. Sarkar C, Basu B, Chakroborty D, Dasgupta PS, Basu S. The immunoregulatory
role of dopamine: an update. Brain Behav Immun. 2010;24:525–8.
18. Hanami K, Nakano K, Saito K, Okada Y, Yamaoka K, Kubo S, et al. Dopamine
D2-like receptor signaling suppresses human osteoclastogenesis. Bone.
2013;56:1–8.
19. Wang Q, Ma Y, Liu D, Zhang L, Wei W. The roles of B cells and their
interactions with fibroblast-like synoviocytes in the pathogenesis of
rheumatoid arthritis. Int Arch Allergy Immunol. 2011;155:205–11.
20. Naylor K, Eastell R. Bone turnover markers: use in osteoporosis. Nat Rev
Rheumatol. 2012;8:379–89.
21. Garnero P, Landewé R, Boers M, Verhoeven A, Van Der Linden S, Christgau S,
et al. Association of baseline levels of markers of bone and cartilage
degradation with long-term progression of joint damage in patients with early
rheumatoid arthritis. Arthritis Rheum. 2002;46:2847–56.
22. Lodder MC, Haugeberg G, Lems WF, Uhlig T, Orstavik RE, Kostense PJ, et al.
Radiographic damage associated with low bone mineral density and
vertebral deformities in rheumatoid arthritis: the Oslo-Truro-Amsterdam
(OSTRA) collaborative study. Arthritis Care Res. 2003;49:209–15.
23. Lu X, Gilbert L, He X, Rubin J, Nanes MS. Transcriptional regulation of the
osterix (Osx, Sp7) promoter by tumor necrosis factor identifies disparate
effects of mitogen-activated protein kinase and NFkB pathways. J Biol
Chem. 2006;281:6297–306.
24. Lehmann W, Edgar CM, Wang K, Cho TJ, Barnes GL, Kakar S, et al. Tumor
necrosis factor alpha (TNF-α) coordinately regulates the expression of
specific matrix metalloproteinases (MMPS) and angiogenic factors during
fracture healing. Bone. 2005;36:300–10.
25. Torikai E, Kageyama Y, Takahashi M, Suzuki M, Ichikawa T, Nagafusa T, et al.
The effect of infliximab on bone metabolism markers in patients with
rheumatoid arthritis. Rheumatology (Oxford). 2006;45:761–4.
26. Vis M, Havaardsholm EA, Haugeberg G, Uhlig T, Voskuyl AE, van de Stadt RJ, et al.
Evaluation of bone mineral density, bone metabolism, osteoprotegerin and
receptor activator of the NFkB ligand serum levels during treatment with
infliximab in patients with rheumatoid arthritis. Ann Rheum Dis. 2006;65:1495–9.
27. Lange U, Teichmann J, Müller-Ladner U, Strunk J. Increase in bone mineral
density of patients with rheumatoid arthritis treated with anti-TNF-α
antibody: a prospective open-label pilot study. Rheumatology (Oxford).
2005;44:1546–8.
28. Bankhurst AD, Husby G, Williams Jr RC. Predominance of T cells in the
lymphocytic infiltrates of synovial tissues in rheumatoid arthritis. Arthritis
Rheum. 1976;19:555–62.
29. Nakken B, Munthe LA, Konttinen YT, Sandberg AK, Szekanecz Z, Alex P, et al.
B-cells and their targeting in rheumatoid arthritis–current concepts and
future perspectives. Autoimmun Rev. 2011;11:28–34.
30. Yeo L, Toellner KM, Salmon M, Filer A, Buckley CD, Raza K, et al. Cytokine
mRNA profiling identifies B cells as a major source of RANKL in rheumatoid
arthritis. Ann Rheum Dis. 2011;70:2022–8.
31. Martín-Escudero JC, Pérez-Castrillón JL, Blanco FS, Arzua-Mouronte D, Bellido
Casado J, Martín JM. Relation between bone mass and catecholamines in
the general population. Horm Res. 2007;68:63–7.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Wei et al. BMC Musculoskeletal Disorders  (2016) 17:352 Page 7 of 7
